Entasis Therapeutics to Present at H.C. Wainwright & Co. Global Life Sciences Conference in London

Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that Dr. Manos Perros, President and Chief Executive Officer, will present at the H.C, Wainwright & Co. Global Life Sciences Conference being held April 7-9, 2019 in London, UK.

Details of the presentation are below:Event: H.C. Wainwright & Co. Global Life Sciences ConferenceDate: Tuesday, April 9, 2019Time: 11:10 AM GMT / 7:10 AM EDT

In addition to his presentation, Dr. Perros will be hosting 1-on-1 investor meetings at the conference. Investors attending the conference who are interested in meeting with Entasis management should contact their H.C. Wainwright representatives.

About EntasisEntasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis’ targeted-design platform has produced a pipeline of product candidates, including ETX2514SUL (targeting A. baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae), and ETX0282CPDP (targeting Enterobacteriaceae infections). Entasis is also using its platform to develop a novel class of antibiotics, non-β-lactam inhibitors of the penicillin-binding proteins (NBPs) (targeting Gram-negative infections). For more information, visit www.entasistx.com.

Entasis Company Contact              Kyle Dow Entasis Therapeutics [phone] [e-mail]

Investor Relations ContactLee RothThe Ruth Group(646) [e-mail]

Media ContactKirsten ThomasThe Ruth Group(508) [e-mail]